Aeras today announced that Danilo Casimiro, Ph.D., has joined the organization as Chief Scientific Officer (CSO) effective February 29. Dr. Casimiro joins Aeras from the Merck Research Laboratories, where he was Executive Director in the Department of Infectious Diseases and Vaccine Research.
The White House plan to address drug-resistant tuberculosis (TB), The National Action Plan for Combating Multidrug-Resistant Tuberculosis, released today, is an important step in the U.S. government’s response to this deadly infectious disease.
The World Health Organization (WHO) released its Global Tuberculosis Report 2015 today, announcing that tuberculosis (TB) caused 1.5 million deaths in 2014, and HIV/AIDS caused 1.2 million deaths last year1.
Rockville, MD, July 20, 2015 – David L. Blumberg, M.B.A., an expert in the life sciences industry, recently joined Aeras’s Board of Directors. He has more than 20 years of business and consulting experience across the life sciences continuum, including large global, specialty, and generic pharmaceuticals, biotech, and medical devices and products.
Aeras announced today a new leadership structure for the nonprofit biotech organization with Jacqueline E. Shea, Ph.D., the current Chief Operating Officer (COO), assuming the role of Chief Executive Officer (CEO), effective August 12. Thomas G. Evans, M.D., will step down as CEO to become Acting Chief Scientific Officer (CSO). Ann M. Ginsberg, M.D., Ph.D., will continue as Chief Medical Officer.